WaferGen Bio-systems, Inc. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Revenue:
Product
License and royalty
Total revenue
Cost of revenue
Gross profit
Operating expenses:
Sales and marketing
Research and development
General and administrative
Total operating expenses
Operating loss
Other income and (expenses):
Interest income
Interest expense
Interest expense, net
Contingent earn-out adjustment
Gain on revaluation of warrant derivative liabilities, net
Liquidated damages for late S-1 registration
Gain on settlement of derivative liability
Loss on extinguishment of debt
Issuance of warrants due to organic change
Gain on liquidation of subsidiary
Miscellaneous expense
Total other income and (expenses)

Net loss before provision for income taxes
Provision for income taxes
Net loss
Accretion on Series A and B convertible preference shares of subsidiary associated with premium
Accretion on Series A-1 Convertible Preferred Stock associated with beneficial conversion feature
Accretion on Series 1 convertible preferred stock associated with beneficial conversion feature
Foreign currency translation adjustments
Total comprehensive loss
Accretion on Series 2 convertible preferred stock associated with beneficial conversion feature
Series A-1 preferred dividend
Net loss attributable to common stockholders
Net loss per share basic and diluted (in Dollars per share)
Shares used to compute net loss per share - basic and diluted
Shares used to compute net loss per share - basic and diluted (in shares)

Comments